Rod-Cone Dystrophy

Rod-cone dystrophy, often called retinitis pigmentosa, is a genetic eye condition that causes a gradual loss of vision. It affects the light-sensitive cells in the back of the eye, known as the retina. The condition primarily damages the "rod" cells, which help us see in dim light and at the edges of our vision. As the disease progresses, it also affects the "cone" cells, which are responsible for sharp central vision and seeing colors. The first symptom most people notice is difficulty seeing at night or in poorly lit areas, a condition called night blindness. Over time, people may experience a narrowing of their side vision, often described as "tunnel vision." While the rate of vision loss varies from person to person, it usually happens slowly over many years. Eventually, the condition can lead to difficulty with reading, recognizing faces, and performing daily tasks. Currently, there is no cure for most types of rod-cone dystrophy, but treatments are available to help manage symptoms and maximize remaining vision. These may include special glasses, magnifying devices, and mobility training. Researchers are actively studying new therapies, including gene therapy and artificial retinas, which offer hope for the future. If you or a family member has been diagnosed with this condition, genetic testing and counseling can provide valuable information about the specific cause and what to expect.

Condition category: Retinal Dystrophy

Prevalence: 1 in 3,000 to 1 in 4,000

Inheritance patterns: Autosomal Dominant, Autosomal Recessive, X-Linked

Age of onset: Variable, often childhood or adolescence

Clinical overview: Note: Rod-Cone Dystrophy is the pathophysiological classification for Retinitis Pigmentosa (RP). In RP, rod photoreceptors degenerate first followed by cones, hence the term rod-cone dystrophy. See the Retinitis Pigmentosa entry for the primary clinical description. This entry focuses on the broader rod-cone dystrophy classification which may include atypical RP presentations. Rod-cone dystrophy, most commonly referred to as retinitis pigmentosa (RP), is a clinically and genetically heterogeneous group of inherited retinal disorders. It is characterized by the primary degeneration of rod photoreceptors, which are responsible for vision in low light, followed by the secondary degeneration of cone photoreceptors, which mediate color vision and central visual acuity. The condition is a leading cause of inherited blindness, affecting approximately 1 in 4,000 individuals worldwide. It can occur as an isolated, non-syndromic condition or as part of a broader systemic syndrome, such as Usher syndrome or Bardet-Biedl syndrome. The clinical presentation typically begins with night blindness in childhood or adolescence, progressing to peripheral visual field loss and, eventually, central vision impairment. Rod-cone dystrophy is associated with numerous OMIM entries reflecting its genetic diversity, including OMIM 268000 (Retinitis Pigmentosa, Autosomal Recessive), OMIM 180100 (Retinitis Pigmentosa 1; RP1), and OMIM 312600 (Retinitis Pigmentosa 2; RP2). The Orphanet number for the broader category of retinitis pigmentosa is ORPHA:791.

Patient and family guide: Rod-cone dystrophy, often called retinitis pigmentosa, is a genetic eye condition that causes a gradual loss of vision. It affects the light-sensitive cells in the back of the eye, known as the retina. The condition primarily damages the "rod" cells, which help us see in dim light and at the edges of our vision. As the disease progresses, it also affects the "cone" cells, which are responsible for sharp central vision and seeing colors. The first symptom most people notice is difficulty seeing at night or in poorly lit areas, a condition called night blindness. Over time, people may experience a narrowing of their side vision, often described as "tunnel vision." While the rate of vision loss varies from person to person, it usually happens slowly over many years. Eventually, the condition can lead to difficulty with reading, recognizing faces, and performing daily tasks. Currently, there is no cure for most types of rod-cone dystrophy, but treatments are available to help manage symptoms and maximize remaining vision. These may include special glasses, magnifying devices, and mobility training. Researchers are actively studying new therapies, including gene therapy and artificial retinas, which offer hope for the future. If you or a family member has been diagnosed with this condition, genetic testing and counseling can provide valuable information about the specific cause and what to expect.

Symptoms and clinical features: The clinical presentation of rod-cone dystrophy typically follows a predictable sequence, reflecting the progressive degeneration of photoreceptors. In the early stages, the predominant symptom is nyctalopia, or night blindness. Patients often report difficulty seeing in dimly lit environments, such as movie theaters or outdoors at dusk, and may require prolonged periods to adapt to the dark. This symptom can manifest in early childhood or adolescence and is a direct result of rod photoreceptor dysfunction. As the disease progresses to the intermediate stages, patients begin to experience a loss of peripheral vision. This often starts as a mid-peripheral ring scotoma (a blind spot in the middle of the visual field) that gradually expands outward and inward. Patients may not initially notice this visual field constriction but may present with a history of frequently bumping into objects or appearing clumsy. The progressive narrowing of the visual field eventually leads to "tunnel vision," where only a small central island of vision remains. In the advanced stages of rod-cone dystrophy, the secondary degeneration of cone photoreceptors becomes clinically apparent. This leads to a decline in central visual acuity, difficulties with color perception, and photophobia (sensitivity to bright light). Patients may struggle with reading, recognizing faces, and performing fine visual tasks. Ultimately, the condition can progress to legal blindness or complete loss of light perception, although the timeline for this progression varies widely among individuals.

Molecular pathology: Rod-cone dystrophy is characterized by the primary degeneration of rod photoreceptors, followed by the secondary loss of cone photoreceptors. The molecular mechanisms underlying this degeneration are diverse, reflecting the genetic heterogeneity of the condition. Mutations can affect various cellular processes essential for photoreceptor survival and function. Many causative genes encode proteins involved in the visual phototransduction cascade. For instance, mutations in the RHO gene, which encodes rhodopsin (the light-sensitive receptor protein in rods), can lead to protein misfolding, accumulation in the endoplasmic reticulum, and subsequent cellular stress and apoptosis. Mutations in genes encoding subunits of phosphodiesterase 6 (PDE6A, PDE6B) disrupt the regulation of cyclic GMP levels, leading to toxic accumulation of cGMP and photoreceptor death. Other affected pathways include the visual cycle (e.g., RPE65, LRAT), which is responsible for regenerating the visual chromophore, and the maintenance of photoreceptor structure and ciliary function (e.g., RPGR, USH2A, MAK). Defects in these structural proteins can impair the transport of essential molecules between the inner and outer segments of photoreceptors, leading to structural instability and eventual cell death. The secondary loss of cones is thought to result from the loss of structural and trophic support normally provided by the rods, as well as increased oxidative stress in the degenerating retina.

Genetics: Rod-cone dystrophy is genetically highly heterogeneous, with mutations in over 80 genes identified to date. It can be inherited in an autosomal dominant (30-40%), autosomal recessive (50-60%), or X-linked (5-15%) manner. Rare mitochondrial and digenic inheritance patterns have also been reported. Common genes associated with autosomal dominant inheritance include RHO (rhodopsin), PRPF31, PRPH2, and RP1. Autosomal recessive forms are frequently caused by mutations in USH2A, CRB1, PDE6A, PDE6B, and ABCA4. X-linked forms are predominantly associated with mutations in the RPGR and RP2 genes. Genotype-phenotype correlations exist but can be variable. For example, mutations in the RHO gene often cause a classic, slowly progressive form of autosomal dominant RP, while mutations in RPGR typically result in a severe, early-onset X-linked form. Some genes, such as USH2A, can cause both non-syndromic rod-cone dystrophy and syndromic forms (Usher syndrome type 2), depending on the specific mutation and its effect on protein function.

Diagnostic evaluation: The diagnosis of rod-cone dystrophy (retinitis pigmentosa) is established through a combination of clinical history, visual field testing, imaging, and electrophysiology. Fundoscopy in early stages may appear normal or show subtle changes, but as the disease progresses, classic signs emerge, including bone-spicule intraretinal pigmentation, arteriolar attenuation, and waxy pallor of the optic disc. Optical coherence tomography (OCT) is crucial for evaluating the macular region, often revealing cystoid macular edema (CME) or progressive thinning of the outer retinal layers. Visual field testing typically demonstrates a mid-peripheral ring scotoma that gradually expands, leading to severe peripheral vision loss or "tunnel vision." Full-field electroretinography (ffERG) is the definitive test for assessing photoreceptor function. In rod-cone dystrophy, dark-adapted (rod) responses are severely reduced or non-detectable early in the disease, with prolonged implicit times. Light-adapted (cone) responses may also be reduced but are relatively preserved compared to rod responses in the early stages. Genetic testing is increasingly important for confirming the diagnosis, identifying the specific causative gene, and determining inheritance patterns. Differential diagnosis includes other inherited retinal dystrophies, such as cone-rod dystrophy (where cone dysfunction precedes rod dysfunction), choroideremia, and syndromic forms of retinitis pigmentosa (e.g., Usher syndrome, Bardet-Biedl syndrome). Acquired conditions like infectious retinitis or autoimmune retinopathy should also be considered.

Differential diagnosis: Differential diagnosis of rod-cone dystrophy includes: (1) Retinitis pigmentosa (typical) — overlapping presentation; rod-cone dystrophy is essentially synonymous with RP in most classifications. (2) Cone-rod dystrophy — cone dysfunction predominates initially. (3) Choroideremia — X-linked, scalloped atrophy. (4) Usher syndrome — hearing loss with RP. (5) Bardet-Biedl syndrome — systemic features with RP. (6) Drug-induced retinopathy — medication history (thioridazine, deferoxamine).

Natural history: The natural history of rod-cone dystrophy is characterized by a progressive decline in visual function, typically spanning several decades. The age of onset and rate of progression vary widely depending on the specific genetic mutation and inheritance pattern. In general, individuals with autosomal dominant forms tend to have a later onset and a slower rate of progression, often retaining useful central vision well into adulthood. Conversely, those with X-linked or autosomal recessive forms typically experience an earlier onset and a more rapid decline, frequently leading to severe visual impairment or legal blindness by mid-adulthood. Prognostic factors include the specific genetic diagnosis, the age of onset of night blindness, and the initial visual field and ERG findings. Early macular involvement, such as the development of cystoid macular edema or macular atrophy, can significantly accelerate the loss of central visual acuity.

Management and treatment research: ### Current Management and Standard of Care Management of rod-cone dystrophy focuses on preserving remaining vision, identifying treatable eye complications, and supporting independence. Care is individualized according to symptoms, retinal findings, and the underlying genetic diagnosis. - **Low-vision rehabilitation:** Low-vision specialists can recommend magnifiers, filtered or telescopic glasses, electronic reading aids, screen-reader settings, improved lighting and contrast, and other assistive technology. Orientation and mobility training, occupational rehabilitation, and school or workplace accommodations may also help. - **Monitoring for eye complications:** Retinal specialists may monitor for cataracts and cystoid macular edema, a buildup of fluid in the macula, the central part of the retina. Depending on the situation, macular edema may be treated with carbonic anhydrase inhibitor medicines, and visually significant cataracts can often be treated surgically. - **Genetic testing and counseling:** Genetic testing may identify the cause of rod-cone dystrophy, clarify inheritance patterns, inform family planning, and help determine eligibility for gene-specific treatments or research studies. ### Approved Therapy There is no treatment approved for all forms of rod-cone dystrophy. - **Voretigene neparvovec-rzyl (Luxturna):** This FDA-approved gene therapy is available for people with confirmed **biallelic (two-copy) RPE65 mutations** and sufficient viable retinal cells. It is delivered by subretinal injection and supplies a working copy of the *RPE65* gene. It is not appropriate for rod-cone dystrophy caused by other genes. ### Investigational Therapies and Research Research studies may include people with rod-cone dystrophy or related inherited retinal diseases. Eligibility can depend on the genetic cause, age, retinal structure and function, vision level, and other study requirements. #### Gene and cell-based approaches - **SPVN20 gene therapy:** A recruiting phase 1/2 open-label study is evaluating the safety, tolerability, and efficacy of SPVN20 in people with rod-cone dystrophy (NCT07807111). Early-phase studies primarily assess safety and appropriate dosing. - **OpCT-001 cell therapy:** The CLARICO study is recruiting adults with primary photoreceptor disease to evaluate the safety of OpCT-001, an investigational photoreceptor cell therapy (NCT06789445). This is a phase 1/2 study. #### Medicines and nutritional approaches - **Disulfiram (Antabuse):** A recruiting phase 1 study is evaluating the effects of disulfiram on visual acuity in people with retinal degeneration (NCT06319872). - **9-cis beta-carotene–rich *Dunaliella* algae extract:** An early phase study in retinitis pigmentosa is enrolling by invitation (NCT07509229). - **Ultevursen:** This investigational antisense oligonucleotide is designed to affect RNA processing. A phase 2 study is evaluating it for retinitis pigmentosa caused by mutations in exon 13 of the *USH2A* gene (NCT06627179). The study is active but not recruiting. #### Natural-history and vision-function studies - The Universal Rare Gene Study collects registry and natural-history information from people with retinal dystrophies associated with rare disease-causing variants (NCT05589714). - The National Eye Institute is recruiting for studies of rod- and cone-mediated visual function (NCT02617966) and virtual-reality mobility assessment of functional vision (NCT04289571). - A recruiting study is examining brain stimulation and orientation-and-mobility skills in adults with vision impairment (NCT07341763). ### Considering a Clinical Trial Clinical trials may provide research assessments or access to investigational approaches, but they do not guarantee benefit. A retinal specialist and genetic counselor can help review potential eligibility, study requirements, possible risks, travel needs, and alternatives. Genetic test results are especially important for studies targeting a specific gene or variant.

Outlook: The prognosis for individuals with rod-cone dystrophy varies significantly depending on the underlying genetic cause and the specific inheritance pattern. While the condition is progressive and ultimately leads to severe visual impairment in many cases, the rate of decline can range from rapid deterioration in early adulthood to a slow progression that allows for the retention of useful central vision into late adulthood. Quality of life is profoundly affected by the progressive loss of independence, mobility challenges, and the psychological impact of impending blindness. However, with appropriate low vision rehabilitation, adaptive technologies, and supportive care, many individuals maintain active and fulfilling lives. Early diagnosis and genetic counseling are crucial for helping patients and families understand their specific prognosis and plan for the future.

Epidemiology: Rod-cone dystrophy, commonly known as retinitis pigmentosa, is the most common inherited retinal dystrophy. The estimated prevalence is approximately 1 in 3,000 to 1 in 4,000 individuals worldwide, affecting over 1.5 million people globally. The condition occurs in all ethnic groups, though specific genetic mutations may be more prevalent in certain populations due to founder effects or consanguinity. There is generally no significant sex predilection in autosomal forms, but X-linked forms predominantly affect males, who typically experience a more severe clinical course.

Selected references: 1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795-1809. PMID: 17113430 2. Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clin Genet. 2013;84(2):132-141. PMID: 23701314 3. Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, Parmeggiani F. Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics. 2011;12(4):238-249. PMID: 22043162 4. Verbakel SK, van Huet RAC, Boon CJF, et al. Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018;66:157-186. PMID: 29545045 5. Duncan JL, Pierce EA, Laster AM, et al. Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps. Transl Vis Sci Technol. 2018;7(4):6. PMID: 30034950